PRINCETON, N.J.— November 1 2023, Certara (Nasdaq: CERT), a global leader in biosimulation, today announced that the Company was listed on Fortune’s Best Workplaces in BioPharma™ 2023 and was certified as a Great Place to Work for the second year in a row. The prestigious certification is based on what current Certara employees say about … Continued
Certara University offers 3 Introductory level Certification Courses. These courses are administered within the learning system of Certara University. You can view additional details and register using the links in the table below. Certification Course Registration Link Price* Phoenix WinNonlin (Part 1) NCA Certification Course Live On-Line – January – February 2024 – June – … Continued
Formedix ryze cloud based clinical metadata repository and SDTM automation suite and Certara Pinnacle 21 data validation platform combine to power faster clinical trials Princeton, NJ – October 10th, 2023 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT) today announced it has acquired Formedix, a provider of clinical metadata repository and clinical trial automation software. The acquisition enhances … Continued
Certara.AI Improves Drug Research & Development Processes with Secure, Client-Specific, A.I. Applications PRINCETON, N. J.—2023年10月5日— Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT), a global leader in biosimulation software, today announced the availability of Certara.AI, a platform designed specifically for the deployment of client-specific generative pre-trained transformers (GPTs) in Life sciences organizations. The majority of GPT models … Continued
Using AI to gain efficiencies for medical writers PRINCETON, N. J.— 2023年10月3日— Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT), a global leader in biosimulation software and advanced drug development solutions, today announced the launch of CoAuthor, a writing software suite designed to revolutionize the creation and review of critical clinical trial documents in the pharmaceutical industry. … Continued
Certara launches Phoenix Hosted, a cloud-based solution of Phoenix™ software PRINCETON, N.J.— 2023年9月19日 – Certara, Inc., a global leader in biosimulation software, today announced the release of Phoenix Hosted. The cloud-based solution Phoenix Hosted empowers PK/PD scientists with seamless access to the industry-leading Phoenix™ WinNonlin and NLME software, within a secured and validated … Continued
Delivers advanced data analysis and visualization capabilities to support nonclinical scientists PRINCETON, N.J.— 2023年8月28日 – Certara, Inc., a global leader in biosimulation, today announced the release of version 11.0 of the SEND Explorer® Product Family. SEND Explorer allows scientists to interactively investigate study data, to efficiently identify dose-response relationships and to effectively communicate data … Continued
グローバルガイドラインに沿って前臨床試験データ管理を最適化するのに役立つソフトウェアの導入Seoul, SOUTH KOREA August 4rd – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT), a global leader in Biosimulation, today announced that a Korea Institute of Toxicology (KIT) have decided to implement Certara’s Pinnacle 21 Enterprise data conformance and submission software and SEND Explorer pre-clinical … Continued
DNDi Utilizing Pinnacle 21 Enterprise (P21E), Certara’s Data Science platform for Biostatistics, Data Management, and Data Standards to Streamline Clinical Data Flow PRINCETON, NJ/NAIROBI, KE, 2023年7月31日 – Certara, Inc. バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT), a global leader in biosimulation software and advanced drug development solutions, today announced a partnership with the Drugs for Neglected Diseases initiative … Continued
2023年6月20日ニュージャージー州プリンストン - バイオシミュレーションのグローバルリーダーであるサターラ（Nasdaq：CERT)は、,ワシントン大学から薬物相互作用ソリューションを買収したことを発表しました。今回の買収により、世界的に有名な科学者チームと、薬物動態学的（PK）薬物相互作用を同定するための主要なサブスクリプションベースのインフォマティクスソリューションDrug Interaction Database (“DIDB”), （「DIDB」）がサターラのポートフォリオに加わります。Used by over … Continued
